KBC Securities - UCB S.A. (UCB) UCB FIRS LOOK: Addl Phase 3 data support dapirolizumabs potential in SLE

Report

KBC Securities

Thomas Vranken

UCB FIRS LOOK: Add'l Phase 3 data support dapirolizumab's potential in SLE

UCB and Biogen presented additional Phase 3 data showing that dapirolizumab pegol (DZP, anti-CD40L) significantly improves fatigue and disease activity in patients with moderate-to-severe systemic lupus erythematosus (SLE). Beyond the positive topline readout in Nov '24, DZP showed superior results over standard care in multiple fatigue and disease remission measures. Accumulate/€214 TP confirmed.

12/06/2025 1 EN

Underlying

UCB S.A.

UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.

See profile

BE0003739530 Euronext Brussels Belgium

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Thomas Vranken

Other Reports on these Companies

ING Financial Markets

Benelux Morning Notes

Belgian telecoms: Orange Belgium's new B2B offensive. BE Semiconductor Industries: Investor Day highlights. Proximus: Sale of Be-Mobile, asset disposals upped from ‘>€500m' to ‘up to €600m'. UCB: To invest in a new US manufacturing site

5h / 9m 5h / 9m 1 EN

KBC Securities

Morning Notes : AGFB BB, BPOST BB, GLPG NA, PROX BB, UCB BB, MAAT FP

: AGFB BB, BPOST BB, GLPG NA, PROX BB, UCB BB, MAAT FP

5h / 32m 5h / 32m 1 EN

KBC Securities

Dollar Weakness The impact on our Benelux Coverage

In general, a weaker USD has a negative impact on Benelux stocks, particularly for companies with significant exports to the US. In this note we selected a list of companies with high US export exposure and we examine the potential impact on FY25 earninings. On top of the weak dollar, rising trade tensions or the introduction of tariffs further harm Benelux exporters. As the dollar depreciates against the euro, European goods become costlier for American consumers. At the same time, revenues earned in U.S. dollars translate into fewer euros. Some Benelux companies suffer mainly from this trans...

5h / 42m 5h / 42m 1 EN

Brederode 1Q25: NAVps down 1.7%; Weakening Dollar Impacts Private Assets

Over 1Q25, NAVps decreased by 1.7% to €139.0ps (vs. €141.4ps at FY24-end). This was mainly due to the private asset portfolio, which recorded a loss of €74.7m on the ~€4.1bn portfolio. The primary reason was the recent decline of the USD. The listed assets generated a modest €6.6m gain, mostly driven by Iberdrola and Enel. During the first quarter, the position in Experian was strengthened, while the position in Nestlé was reduced. We currently estimate the NAVps at €140.0, implying a 13.2% discount. This is higher than the 5yr average of 11.4%, but lower than the more relevant 2yr average of ...

5h / 16m 5h / 16m 1 EN

Jacob Mekhael

Jacob Mekhael

Galapagos Updated NHL phase 1/2 GLPG5101 data at EHA shows decentralised POC

Galapagos will present new data from the ongoing Phase 1/2 (ATALANTA-1) study of GLPG5101 (CD19 CAR-T) at the European Hematology Association (EHA) Congress, being held 12-15 June. The results demonstrate POC for a 7 day vein-vein de-centralised CAR-T manufacturing process. Combined with the previously reported safety differentiation, we believe this could support strategic discussions as the company is exploring such options for its cell therapy business. We reiterate our Buy rating and € 37 TP.

5h / 26m 5h / 26m 1 EN

Jacob Mekhael

Jacob Mekhael

MaaT Pharma Updated MaaT013 aGvHD EAP data at EHA shows consistent outcomes

MaaT reported updated early access program (EAP) results for MaaT013 (microbiome therapy, enema formulation) in aGvHD at EHA, being held 12-15 June. The data, which was previously shared in the abstract last month, shows that the response rates and overall survival observed in the steroid refractory and ruxulitinib resistant subset of patients (n=70) are in line with what was observed in the phase 3 ARES trial. In our view, this points to the consistency of outcomes with MaaT013 in this patient population where no current standard of care exists. With regulatory submission in Europe completed,...

5h / 29m 5h / 29m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

UCB FIRS LOOK: Add'l Phase 3 data support dapirolizumab's potential in SLE

We are a financial services provider for several types of professional clients, each with distinct needs.

Benelux Morning Notes

Morning Notes : AGFB BB, BPOST BB, GLPG NA, PROX BB, UCB BB, MAAT FP

Dollar Weakness The impact on our Benelux Coverage

Brederode 1Q25: NAVps down 1.7%; Weakening Dollar Impacts Private Assets

Galapagos Updated NHL phase 1/2 GLPG5101 data at EHA shows decentralised POC

MaaT Pharma Updated MaaT013 aGvHD EAP data at EHA shows consistent outcomes

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe